Imago BioSciences (NASDAQ: IMGO), a clinical-stage biopharmaceutical company, has announced that the first participant has been dosed in a Phase 2 study of its investigational drug bomedemstat in combination with ruxolitinib for the treatment of myelofibrosis.

The open-label study, led by Dr. Harinder Gill at the Department of Medicine at Queen Mary Hospital and the University of Hong Kong, will enroll approximately 20 participants diagnosed with myelofibrosis and will assess the safety and efficacy of the combination therapy.

Bomedemstat has shown promising results in Phase 2 studies for the treatment of myelofibrosis and essential thrombocythemia, and has received Orphan Drug and Fast Track Designation from the U.S. FDA and Orphan Designation from the European Medicines Agency for the treatment of both conditions.

“We are excited that the University of Hong Kong has interest in exploring the potential use of bomedemstat in combination with ruxolitinib for the treatment of myelofibrosis,” said Hugh Y. Rienhoff, Jr., M.D., Chief Executive Officer of Imago BioSciences. “Bomedemstat, through the inhibition of LSD1, regulates stem cell activity as well as the maturation of megakaryocytes, both of which are key to the pathophysiology of MF. This study explores the possibility that this new combination regimen will serve as a treatment option for patients who have had inadequate symptom relief or spleen volume reduction with ruxolitinib alone.”

Imago is currently evaluating bomedemstat as a potentially disease-modifying therapy in two Phase 2 clinical trials for the treatment of essential thrombocythemia and myelofibrosis.

Shares of Imago BioSciences trade on the NASDAQ under the ticker symbol IMBO. For more information visit www.imagobio.com.